Eikon Therapeutics has raised $381 million from its IPO, at the top end of its expectations, in another sign of a pickup in appetite for new biotech listings on the Nasdaq. The South San Francisco ...

Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...

Beneficial Owner of more than 10% of a Class of Security Purchase at price 18.00 per share. Indirect 4,999,968 Feb 4, 2026 ...

OpenAI announced they are extending the Responses API to make it easier for developer to build agentic workflows, adding ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Eikon Therapeutics, Inc. ( (EIKN)) just unveiled an update. On February 6, 2026, Eikon Therapeutics, Inc. completed its initial public offering of common stock and, in connection with the transaction, ...

All in all, your first RESTful API in Python is about piecing together clear endpoints, matching them with the right HTTP ...

AI agent on a microcontroller.

Big Tech is reshaping the funding landscape for new nuclear technologies as it seeks to bolster electricity supply for power-hungry AI data centers, inking deals that offer nuclear companies both ...

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...